Released: September 26, 2022
Recorded: September 15, 2022
Expiration Date: September 26, 2025

About This Webinar
About 3.4 million people in the United States live with active epilepsy. Epilepsy is a complex spectrum of disorders characterized by recurrent seizures. Seizures are not the only challenge that people with epilepsy face, as they are often confronted with complex medication regimens, lifestyle adjustments, co-morbid disease, disability, under- or unemployment, limited access to transportation, and stigma. Even when seizures are well controlled, challenges often persist throughout the course of the disease leading to increased morbidity, mortality, and a decreased quality of life. Each individual impacted by epilepsy presents a complex set of medical and psychosocial issues for medical providers to manage in the clinic setting, and for patients to self-manage in their homes and diverse communities.

This webinar provides an overview of epilepsy, the challenges of living with and managing epilepsy, and an introduction to telehealth accessible evidence-based epilepsy self-management programs.

This webinar is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,500,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

Presenter
Elaine T. Kiriakopoulos, MD, MSc
Geisel School of Medicine at Dartmouth College

Moderator
David Ficker, MD
University of Cincinnati

Learning Objectives:
At the end of this webinar, attendees should be able to:

• Describe the public health challenges of epilepsy
• Define the diagnosis of epilepsy and medication resistant epilepsy
• Identify common causes of epilepsy
• Describe current treatment options for epilepsy
• Discuss common medical and psychosocial comorbidities in epilepsy
• Explain the benefits of standardized self-management programs for people with epilepsy

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity's content.

The following individuals contributed to this activity’s content.
Planning Committee* and Faculty

Alexis Griffith, MPH
American Epilepsy Society

Shawna Strickland, PhD, CAE, RRT, FAARC
American Epilepsy Society

Elaine T. Kiriakopoulos, MD, MSc
Geisel School of Medicine at Dartmouth College

CME Reviewer
Elaine Seto, MD, PhD

American Epilepsy Society Staff Planners
Alexis Griffith, MPH
Shawna Strickland, PhD, CAE, RRT, FAARC
Kandice Kidd, MA
Cristina Graham

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards of Integrity and Independence in Accredited Continuing Education, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.